Identifying risk factors for refractory febrile neutropenia in patients with lung cancer

Journal of Infection and Chemotherapy

Volumn 18, Issue 1, 2012, Pages 53-58

  Fujita, Masaki ^a,b   Tokunaga, Shoji ^c   Ikegame, Satoshi ^a   Harada, Eiji ^a   Matsumoto, Takemasa ^b   Uchino, Junji ^b   Watanabe, Kentaro ^b   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

CRP; Fever; Risk factor; Severity; Solid tumor; Supportive care

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CARBAPENEM; CEPHALOSPORIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; INFECTION RISK; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE;

EID: 84862135207     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0283-5     Document Type: Article

References (16)

1. Klastersky J. Febrile neutropenia. CurrOpinOncol. 1993;5:625-32. (Pubitemid 23197460)
2. Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39:S49-52. (Pubitemid 38971476)
3. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-51. (Pubitemid 34194843)
4. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-51. (Pubitemid 30644129)
5. Hanna N, Shepherd FA, Fossella FV, Pereira JR, de Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed vs docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-97. (Pubitemid 41079796)
6. Wailoo A, Sutton A, Morgan A. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-Analysis. Br J Cancer. 2009;100: 436-41.
7. Pompei P, Charlson ME, Ales K, MacKenzie CR, Norton M. Relating patient characteristics at the time of admission to outcomes of hospitalization. J Clin Epidemiol. 1991;44:1063-9.
8. Niho S, Ohe Y, Goto K, Ohmatsu H, Matsumoto T, Kubota K, et al. Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer. Jpn J Clin Oncol. 2004;34:69-73. (Pubitemid 43115321)
9. Tillett WS, Francis T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med. 1930;52:561-71.
10. Thiem U, Niklaus D, Sehlhoff B, Stückle C, Heppner HJ, Endres HG, et al. C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-Acquired pneumonia. Age Ageing. 2009;38:693-7.
11. Hedlund J. Community-Acquired pneumonia requiring hospitalisation. Factors of importance for the short-And long term prognosis. Scand J Infect Dis Suppl. 1995;97:1-60.
12. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-Acquired pneumonia. Am J Med. 2008;121:219-25. (Pubitemid 351317927)
13. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother. 1996;40: 1108-15.
14. Fleischhack G, Hartmann C, Simon A, Wulff B, Havers W, Marklein G, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother. 2001;47:841-53. (Pubitemid 32519833)
15. Fujita M, Ouchi H, Inoue Y, Inoshima I, Ohshima T, Yoshimura C, et al. Clinical efficacy and safety of cefepime in febrile neutropenic patients with lung cancer. J Infect Chemother. 2010;16: 113-7.
16. Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, Gonzalez V, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer. 2005; 104:205-12. (Pubitemid 40847770)